Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Octreotide
100%
Pasireotide
100%
Superiority Study
100%
Long-term Release
88%
Octreotide Long-acting Release
88%
Insulin-like Growth factor-1
55%
Biochemical Control
55%
Upper Normal Limit
22%
Medical Therapy
11%
Life Expectancy
11%
Prospective Randomized Trial
11%
Medical Treatment
11%
Titration
11%
New Treatment Options
11%
Cardiac Magnetic Resonance Imaging (cMRI)
11%
Hyperglycemia
11%
Oral Glucose Tolerance Test
11%
Recommended Dose
11%
Pituitary Surgery
11%
Randomized Double-blind Study
11%
Normal Limits
11%
Pituitary Adenoma
11%
Long-acting Octreotide
11%
Naïve Patients
11%
Dose Increase
11%
Related Adverse Events
11%
Medicine and Dentistry
Octreotide
100%
Acromegaly
100%
Pasireotide
100%
Arm
11%
Magnetic Resonance Imaging
11%
Morbidity
11%
Life Expectancy
11%
Pituitary Surgery
11%
Pituitary Adenoma
11%
Hyperglycemia
11%
Titrimetry
11%
Drug Dose Increase
11%
Oral Glucose Tolerance Test
11%
Recommended Drug Dose
11%
Treatment Option
11%
Adverse Event
11%
Nursing and Health Professions
Acromegaly
100%
Octreotide
100%
Pasireotide
100%
Adverse Event
11%
Morbidity
11%
Life Expectancy
11%
Nuclear Magnetic Resonance Imaging
11%
Hypophysis Adenoma
11%
Gold Standard
11%
Hyperglycemia
11%
Drug Dose Increase
11%
Titrimetry
11%
Oral Glucose Tolerance Test
11%
Recommended Drug Dose
11%
Efficacy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acromegaly
100%
Octreotide
100%
Pasireotide
100%
Adverse Event
11%
Morbidity
11%
Life Expectancy
11%
Hypophysis Adenoma
11%
Hyperglycemia
11%
Glucose
11%